glp-1 2026 Oral Market to Rise at 35.05% CAGR till 2035 Novo cuts GLP-1 prices 70%,

111 The only acceptable alternative endpoint in drug development, histological evidence, consists of the resolution of steatohepatitis and no worsening of liver fibrosis, or improvement in liver fibrosis of at least one stage without worsening of steatohepatitis

While traditionally considered first-line therapy, current American Diabetes Association guidance emphasizes a person-centered approach to initial medication selection based on comorbidities, treatment goals, and patient preferences

[Formation of 3-dehydrocarnitine from L-carnitine through the action of a Pseudomonas aeruginosa enzyme]

Wei R, Ma S, Wang C, et al